|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0322 EUR | +6.62% |
|
+8.78% | +2.55% |
| 25-10-15 | GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report | CI |
| 25-10-15 | Geneuro SA postpones publication of half-yearly financial report | RE |
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | - | |||||
Other Revenues, Total | - | - | - | - | - | |||||
Total Revenues | - | - | - | - | - | |||||
Gross Profit | - | - | - | - | - | |||||
Selling General & Admin Expenses, Total | 3.76M | 3.3M | 2.68M | 3.25M | 3.05M | |||||
Stock-Based Compensation (IS) | - | 1.36M | - | 589K | - | |||||
R&D Expenses | 5.22M | 4.12M | 3.66M | 7.97M | 11.3M | |||||
Other Operating Expenses | 10.3K | 38.2K | 23.8K | 12.7K | 1.5K | |||||
Other Operating Expenses, Total | 8.99M | 8.82M | 6.37M | 11.82M | 14.36M | |||||
Operating Income | -8.99M | -8.82M | -6.37M | -11.82M | -14.36M | |||||
Interest Expense, Total | -442K | -72.3K | - | - | - | |||||
Interest And Investment Income | 5.9K | - | - | 7.6K | 75.9K | |||||
Net Interest Expenses | -436K | -72.3K | - | 7.6K | 75.9K | |||||
Currency Exchange Gains (Loss) | -28.1K | -61.7K | 53.9K | -118K | -326K | |||||
Other Non Operating Income (Expenses) | -6.5K | -4.8K | -506K | -269K | -146K | |||||
EBT, Excl. Unusual Items | -9.46M | -8.96M | -6.82M | -12.2M | -14.75M | |||||
EBT, Incl. Unusual Items | -9.46M | -8.96M | -6.82M | -12.2M | -14.75M | |||||
Income Tax Expense | - | - | - | 2.1K | 4.2K | |||||
Earnings From Continuing Operations | -9.46M | -8.96M | -6.82M | -12.2M | -14.76M | |||||
Net Income to Company | -9.46M | -8.96M | -6.82M | -12.2M | -14.76M | |||||
Net Income - (IS) | -9.46M | -8.96M | -6.82M | -12.2M | -14.76M | |||||
Net Income to Common Incl Extra Items | -9.46M | -8.96M | -6.82M | -12.2M | -14.76M | |||||
Net Income to Common Excl. Extra Items | -9.46M | -8.96M | -6.82M | -12.2M | -14.76M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.65 | -0.45 | -0.32 | -0.51 | -0.59 | |||||
Basic EPS - Continuing Operations | -0.65 | -0.45 | -0.32 | -0.51 | -0.59 | |||||
Basic Weighted Average Shares Outstanding | 14.56M | 19.97M | 21.28M | 23.9M | 24.84M | |||||
Net EPS - Diluted | -0.65 | -0.45 | -0.32 | -0.51 | -0.59 | |||||
Diluted EPS - Continuing Operations | -0.65 | -0.45 | -0.32 | -0.51 | -0.59 | |||||
Diluted Weighted Average Shares Outstanding | 14.56M | 19.97M | 21.28M | 23.9M | 24.84M | |||||
Normalized Basic EPS | -0.41 | -0.28 | -0.2 | -0.32 | -0.37 | |||||
Normalized Diluted EPS | -0.41 | -0.28 | -0.2 | -0.32 | -0.37 | |||||
Supplemental Items | ||||||||||
EBITDA | -8.95M | -8.77M | -6.32M | -11.78M | -14.32M | |||||
EBITA | -8.99M | -8.82M | -6.37M | -11.82M | -14.36M | |||||
EBIT | -8.99M | -8.82M | -6.37M | -11.82M | -14.36M | |||||
EBITDAR | -8.9M | -8.7M | -6.24M | -11.7M | -14.24M | |||||
Effective Tax Rate - (Ratio) | - | - | - | -0.02 | -0.03 | |||||
Total Current Taxes | - | - | - | - | - | |||||
Total Deferred Taxes | - | - | - | - | - | |||||
Normalized Net Income | -5.91M | -5.6M | -4.26M | -7.62M | -9.22M | |||||
Interest on Long-Term Debt | - | 9.1K | - | - | - | |||||
Non-Cash Pension Expense | 86.5K | 19.2K | -400K | 51.9K | -83.8K | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 3.7M | 3.23M | 2.59M | 3.17M | 2.97M | |||||
Research And Development Expense From Footnotes | 6.17M | 4.71M | 4.89M | 9.83M | 12.49M | |||||
Net Rental Expense, Total | 46.2K | 77.1K | 82.9K | 80.8K | 82.7K | |||||
Imputed Operating Lease Interest Expense | 37.57K | 8.85K | - | - | - | |||||
Imputed Operating Lease Depreciation | 8.63K | 68.25K | - | - | - | |||||
Stock-Based Comp., R&D Exp. (Total) | 60.2K | 37.6K | 40.7K | 60.7K | 57.3K | |||||
Stock-Based Comp., G&A Exp. (Total) | 22.7K | 68.9K | 106K | 174K | 188K | |||||
Stock-Based Comp., Other (Total) | 300 | 1.36M | 100 | 589K | - | |||||
Total Stock-Based Compensation | 83.2K | 1.47M | 147K | 824K | 245K |
- Stock Market
- Equities
- GNRO Stock
- Financials GeNeuro SA
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















